11 Explore relationship of trial mean comorbidity counts to trial characteristics

We noticed that the ratio between trial and primary care comorbidity counts showed substantial variation. This was true even within the same indication. We therefore performed an exploratory analysis to identify if any trial-characteristics were associated with the trial comorbidity count.

As the following plots show, there was no visual evidence of associations between the comorbidity count and any of the following characteristics : -

- Start date of the trial
- number of trial participants
- sponsor
- drug class
- number of conditions featured in the inclusion criteria
- number of conditions featured in the exclusion criteria

The number of conditions was defined using the MeSH tree as per section Trial eligibility criteria section.




Figure S11.1: Sponsors and number of participants

Alzheimers_Disease	Asthma	Atrial_Fibrillation	Axial_Spondyloarthritis	3enign_Prostatic_Hyperplasia		
2-				•		
1 - • •	•	•	• •			
-	etes_Mellitus_Type_2_plus_	sfunction_Benign_Prostatic_	Hypertension	Hypertension_Pulmonary		
2-	•			•	spor	nsor
) –	•		1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -		•	Boehringer Ingelh
Inflammatory_bowel_disease	Migraine	Osteoarthritis	Osteoporosis	Parkinson_Disease	•	GSK
2 -		•		•	•	Janssen
1 - 1 - 1 - 1 - 1 - 1 - 1 - Psoriasis 2 -	N 8			8	•	Lilly
) -	Descriptio orthvitio	any Disease Chronic Obst	Dulmanany, Filozonia	Dections Loss Cumdrama	•	Novartis
Psoriasis	Psoriatic_arthritis	nary_Disease_Chronic_Obst	Pulmonary_Fibrosis	Restless_Legs_Syndrome	•	Roche
2- 1- • \$	•	*2-	•	*	•	Takeda
) - • • • • rheumatoid_arthritis	• /stemic_Lupus_Erythematos	Thromboembolism	100 1000 10000	100 1000 10000		
2- 1-						

Figure S11.2: Sponsors and number of participants

Alzheimers_Disease	Asthma	Atrial_Fibrillation	Axial_Spondyloarthritis	lenign_Prostatic_Hyperplasia				
	•	•	• •	• •	atc	_5		
	es_Mellitus_Type_2_plus_	sfunction_Benign_Prostatic_	Hypertension	Hypertension_Pulmonary	•	A10BG	٠	L0
					•	A10BH	٠	L0
	••	•	14		•	A10BJ	٠	L0
nflammatory_bowel_disease	•		• •		•	A10BK	٠	LC
nflammatory_bowel_disease	Migraine	Osteoarthritis	Osteoporosis	Parkinson_Disease	•	B01AE	٠	M
-		•		•	•	C02AC	٠	M
				8	•	C03AA	٠	N
Psoriasis	Psoriatic_arthritis	ary_Disease_Chronic_Obst	Pulmonary Fibrosis	Restless_Legs_Syndrome	•	C07AA	٠	N
Psoriasis	- sonauc_artimus	lary_Disease_Chronic_Obsi	Fullionary_1 brosis	Resuess_Legs_Syndrome	•	C09AA	•	N
		N 24	•	÷	•	C09CA	٠	R
· · ·	••				•	G04BE	٠	R
rheumatoid_arthritis	temic_Lupus_Erythematos	Thromboembolism	00 1000 10000	100 1000 10000	•	H05AA	٠	R
- •					•	L01XE	٠	NA
		• •						

Figure S11.3: Drug class and number of participants




Figure S11.4: Inclusion Criteria and number of participants




Figure S11.5: Exclusion Criteria and number of participants Previous Next